Effect of therapeutic plasma exchange on pulmonary haemorrhagic syndrome due to leptospirosis; an open-labeled randomized clinical trial

Dr Nalaka Herath0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•Age 15 to 80 , with lung hemorrhages due to leptospirosis.
•Diagnosis of leptospirosis: Patients with a clinical picture suggestive of leptospirosis and confirmed with PCR, MAT or both)
•Definition of leptospirosis associated pulmonary hemorrhage: Patient with confirmed leptospirosis presenting with haemoptysis, arterial hypoxemia (Acute Lung Score < 2.5), haemoglobin drop (>10% from the previous value), or diffused alveolar shadows in the chest radiograph. The above manifestations should not have an alternative explanation.

•- Chronic kidney disease Stages iii, iv, v
•- Chronic hepatitis and liver cirrhosis of any etiology (compensated or decompensated)
•- Clinically manifested chronic obstructive airway disease, bronchial asthma, lung fibrosis
•- Pregnant women
•- Patients aged <15 and > 80 years
•- Patients who are haemodynamically unstable for TPE will also be excluded from the study.

发起方

Dr Nalaka Herath